Metagenome-wide association of gut microbiome features for schizophrenia by Zhu, Feng et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Metagenome-wide association of gut microbiome features for schizophrenia
Zhu, Feng; Ju, Yanmei; Wang, Wei; Wang, Qi; Guo, Ruijin; Ma, Qingyan; Sun, Qiang; Fan,
Yajuan; Xie, Yuying; Yang, Zai; Jie, Zhuye; Zhao, Binbin; Xiao, Liang; Yang, Lin; Zhang, Tao;
Feng, Junqin; Guo, Liyang; He, Xiaoyan; Chen, Yunchun; Chen, Ce; Gao, Chengge; Xu, Xun;
Yang, Huanming; Wang, Jian; Dang, Yonghui; Madsen, Lise; Brix, Susanne; Kristiansen,
Karsten; Jia, Huijue; Ma, Xiancang
Published in:
Nature Communications
DOI:
10.1038/s41467-020-15457-9
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Zhu, F., Ju, Y., Wang, W., Wang, Q., Guo, R., Ma, Q., ... Ma, X. (2020). Metagenome-wide association of gut
microbiome features for schizophrenia. Nature Communications, 11, [1612]. https://doi.org/10.1038/s41467-020-
15457-9
Download date: 14. May. 2020
ARTICLE
Metagenome-wide association of gut
microbiome features for schizophrenia
Feng Zhu 1,19,20, Yanmei Ju2,3,4,5,19,20, Wei Wang6,7,8,19,20, Qi Wang 2,5,19,20, Ruijin Guo2,3,4,9,19,20,
Qingyan Ma6,7,8, Qiang Sun2,10, Yajuan Fan6,7,8, Yuying Xie11, Zai Yang6,7,8, Zhuye Jie2,3,4, Binbin Zhao6,7,8,
Liang Xiao 2,3,12, Lin Yang6,7,8, Tao Zhang 2,3,13, Junqin Feng6,7,8, Liyang Guo6,7,8, Xiaoyan He6,7,8,
Yunchun Chen6,7,8, Ce Chen6,7,8, Chengge Gao6,7,8, Xun Xu 2,3, Huanming Yang2,14, Jian Wang2,14,
Yonghui Dang15, Lise Madsen2,16,17, Susanne Brix 2,18, Karsten Kristiansen 2,17,20✉, Huijue Jia 2,3,4,9,20✉ &
Xiancang Ma 6,7,8,20✉
Evidence is mounting that the gut-brain axis plays an important role in mental diseases fueling
mechanistic investigations to provide a basis for future targeted interventions. However,
shotgun metagenomic data from treatment-naïve patients are scarce hampering compre-
hensive analyses of the complex interaction between the gut microbiota and the brain. Here
we explore the fecal microbiome based on 90 medication-free schizophrenia patients and 81
controls and identify a microbial species classifier distinguishing patients from controls with an
area under the receiver operating characteristic curve (AUC) of 0.896, and replicate the
microbiome-based disease classifier in 45 patients and 45 controls (AUC= 0.765). Functional
potentials associated with schizophrenia include differences in short-chain fatty acids synth-
esis, tryptophan metabolism, and synthesis/degradation of neurotransmitters. Transplantation
of a schizophrenia-enriched bacterium, Streptococcus vestibularis, appear to induces deficits in
social behaviors, and alters neurotransmitter levels in peripheral tissues in recipient mice. Our
findings provide new leads for further investigations in cohort studies and animal models.
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Schizophrenia is a severe psychiatric disorder associated withhallucinations, delusions, and thought disorders perturbingperception and social interaction1. The etiology of schizo-
phrenia is not elucidated, but assumed to be multifactorial
involving genetic and environmental factors. Abnormalities of
neurotransmitter systems have been extensively studied especially
focusing on aberration of signaling involving dopamine, gluta-
mate, and γ-aminobutyric acid (GABA)2–4. Accumulating evi-
dence indicates that schizophrenia may be a systemic disorder
with neuropsychiatric conditions in addition to psychosis5. Fur-
thermore, the importance of inflammation6 and the involvement
of the gastrointestinal system7 in schizophrenia have received
attention.
The gut microbiota is reported to play an important role in
neurogenerative processes, and perturbation of the microbiota
and microbial products have been demonstrated to affect beha-
vior8–10. Changes in the gut microbiota have been associated with
neurological11 and neurodevelopmental disorders12,13, and
recently also by an independent study of schizophrenia14. It was
recently reported that fecal transfer of the gut microbiota from
patients with schizophrenia induces schizophrenia-associated
behaviors in germ-free recipient mice accompanied with altered
levels of glutamate, glutamine, and GABA in the hippocampus14.
However, the identity and functionality of the specific bacteria
responsible for mediating changes in the behavior of recipient
mice are unknown15,16. Thus, the composition and functional
capacity of the gut microbiota in relation to schizophrenia need to
be systematically examined. Taxonomic and functional profiling
of the gut microbiota is required for functional understanding of
the gut microbiota17. Metagenomic shotgun sequencing com-
bined with bioinformatics tools enables better characterization of
the microbiota18, including a more accurate prediction of biolo-
gical features of the microbes and their potential influence on
host physiology19.
Here, we report on a metagenome-wide association study
(MWAS) using 171 samples (90 cases and 81 controls) and
validate the results by analyzing additional 90 samples (45 cases
and 45 controls). The functional changes characterizing the
schizophrenia gut microbiota are determined using pathway/
module analysis based on the Kyoto Encyclopedia of Genes and
Genomes (KEGG) and a recently developed gut–brain module
(GBM) analysis of fecal metagenomes20. The possible role of one
particular schizophrenia-enriched gut bacterial species, Strepto-
coccus (S.) vestibularis, is explored by transplanting this bacterium
into the gut of the mice with antibiotic-induced microbiota
depletion and observing its effects on animal behavior and brain
neurochemicals.
Results
The gut microbiota profile of schizophrenic patients. We car-
ried out shotgun sequencing on fecal samples from 90
medication-free patients and 81 healthy controls (for demo-
graphic and clinical characteristics see Supplementary Data 1–3)
and obtained an average of 11.46 gigabases (Gb) sequence data
per sample and mapped the high-quality reads onto a compre-
hensive reference gene catalog of 11.4 million genes21 (Supple-
mentary Data 4).
The gut microbiota in schizophrenic patients showed greater α
diversity at the genus level (P= 0.027, Wilcoxon rank-sum test),
higher β diversity at the genus level (P < 0.001, Wilcoxon rank-
sum test) and microbial gene level (P < 0.001, Wilcoxon rank-sum
test) and comprised more genes compared with healthy controls
(Supplementary Fig. 1). Out of a total of 360 metagenomic
operational taxonomic units (mOTUs)22, 83 mOTUs showed
significant differences in relative abundance between patients and
controls (P < 0.05 and false discovery rate (FDR)= 0.136,
Wilcoxon rank sum test and Storey’s FDR method; Supplemen-
tary Data 5a). After adjusting for BMI, age, sex, and diet, these 83
mOTUs were still significant (Supplementary Data 5a). The gut
microbiota in schizophrenic patients harbored many facultative
anaerobes such as Lactobacillus fermentum, Enterococcus faecium,
Alkaliphilus oremlandii, and Cronobacter sakazakii/turicensis,
which are rare in a healthy gut. Additionally, bacteria that are
often present in the oral cavity, such as Veillonella atypica,
Veillonella dispar, Bifidobacterium dentium, Dialister invisus,
Lactobacillus oris, and Streptococcus salivarius were more
abundant in patients with schizophrenia than in healthy controls,
indicating a close association between the oral and the gut
microbiota in schizophrenia.
We then constructed a mOTU network to depict the co-
occurrence correlation between the schizophrenia-associated gut
bacteria (Fig. 1). Schizophrenia-enriched mOTUs were more
interconnected than control-enriched mOTUs (Spearman’s
correlation coefficient <−0.3 or >0.3, P < 0.05). The mOTU
species from the genera Streptococcus and Veillonella showed
positive cross-correlations. Moreover, the majority of the species
in these two clusters of correlated mOTUs originated from the
oral cavity, again pointing to the relation between oral
resident bacteria and gut bacteria, suggesting that oral resident
bacteria in a synergistic manner may colonize the gut in
schizophrenic patients (Fig. 1 and Supplementary Data 5a).
Functional modules and pathways enriched in the gut
microbiota of patients relative to controls were analyzed using
the KEGG database (Supplementary Data 6). The relative
enrichment of 579 KEGG modules and 323 KEGG pathways
varied significantly between the two groups. Schizophrenia-
depleted microbial functional modules included pectin degrada-
tion, lipopolysaccharide biosynthesis, autoinducer-2 (AI-2) trans-
port system, glutamate/aspartate transport system, beta-carotene
biosynthesis, whereas schizophrenia-enriched functional modules
included methanogenesis, the gamma-aminobutyrate (GABA)
shunt, and transport system of manganese, zinc, and iron
(Supplementary Data 6).
Neuroactive potential of schizophrenia-related bacteria. We
next compared the altered microbial neuroactive potential of the
gut microbiota of schizophrenic patients with the controls at the
species level using the method reported by Valles-Colomer
et al.20. We mapped the metagenomic data of the 171 samples to
a genome database including the 42 microbial species that were
detected based on the 83 schizophrenia-associated mOTUs using
PanPhlan23 and calculated the prevalence of species-level
microbes. We then determined whether the abundance of 56
previously reported gut-brain modules (GBMs)20, present in each
microbial species, varied significantly between schizophrenic
patients and controls. The GBM set of each microbial species was
obtained by cross-checking GBM-related genes and the species
gene repertoires (Supplementary Data 7a). The frequency of the
occurrence of each GBM within each species was compared
between patients and controls using a Chi-squared test (Supple-
mentary Data 7b). Schizophrenia-associated GBMs included
short-chain fatty acid synthesis (acetate, propionate, butyrate, and
isovaleric acid), tryptophan metabolism, and the synthesis of
several neurotransmitters, such as glutamate, GABA, and nitric
oxide (Fig. 2).
We chose to validate the presence of the GBM associated with
tryptophan metabolism in schizophrenia, as tryptophan metabo-
lism is modulated by the gut microbiota and implicated in
schizophrenia pathogenesis24,25. Hence, serum tryptophan meta-
bolites were measured in patients and controls and correlated
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with the presence of tryptophan modules in the gut microbiota.
In agreement with the higher abundance of tryptophan
metabolisms related GBMs, we observed lower serum tryptophan
levels and higher kynurenic acid (KYNA) levels in schizophrenic
patients(Supplementary Fig. 2a, c). Moreover, serum tryptophan
levels were negatively correlated with the abundances of 38
bacterial species enriched in schizophrenic patients and positively
correlated with 6 bacterial species enriched in controls (Supple-
mentary Fig. 2d). Similarly, serum KYNA levels were positively
correlated with 10 schizophrenia-enriched bacterial species and
negatively correlated with 3 control-enriched bacterial species
(Supplementary Fig. 2d). Thus, an altered gut microbiota may be
associated with changes in serum levels of tryptophan and KYNA
in schizophrenia.
Gut microbial species characteristic of schizophrenia. To
identify novel gut bacterial species associated with schizophrenia
and evaluate their diagnostic values, we first constructed a set of
random forest disease classifiers based on gut mOTUs. We per-
formed a five-fold cross-validation procedure ten times on 90
patients and 81 controls. Twenty six gut mOTUs reached the
lowest classifier error in the random forest cross validation, and
the area under the receiver operating characteristic curve (AUC)
of the model was 0.896 (Fig. 3a, b). This microbial based classifier
was not significant influenced by age, gender, BMI, and diet style.
(Supplementary Data 8). This discriminatory model was validated
on an additional validation cohort consisting 45 patients taking
antipsychotics and 45 controls (Supplementary Data 9). The
model still distinguished patients from controls with an AUC of
0.765. Among the 26 mOTUs included in the classifier, 11 bac-
terial species with taxonomic identity were significantly enriched
in schizophrenia, namely Akkermansia muciniphila, Bacteroides
plebeius, Veillonella parvula, Clostridium symbiosum, Eubacter-
ium siraeum, Cronobacter sakazakii/turicensis, S. vestibularis,
Alkaliphilus oremlandii, Enterococcus faecium, Bifidobacterium
longum, and Bifidobacterium adolescentis. Some of these micro-
bial species were significantly associated with symptom severity,
cognitive performance, and diagnosis (Fig. 3c).
We next performed metagenomic analysis on the fecal samples
from 38 of the 90 patients after 3-months of treatment (27 with
risperidone and 11 with other antipsychotics, shown in
Supplementary Data 1). The psychotic symptoms and cognitive
impairment improved greatly along with treatment (Supplemen-
tary Fig. 3). However, only approximately half of mOTUs that
distinguished SCZ patients from controls returned to the levels in
controls after treatment (Fig. 3d). As the sample size of the
follow-up patients was smaller, the statistical significance thresh-
old was increased from 0.05 to 0.1. Of the 26 identified microbial
species, 20 species remained significantly changed between 81
controls and 38 baseline patients (P < 0.1, FDR= 0.44, Benjamini
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and Hochberg method, Fig. 3d). After 3-months of treatment, the
abundances of 12 of these 26 mOTUs remained significantly
changed compared with the 81 controls (P < 0.1, FDR= 0.33,
Benjamini and Hochberg method, Supplementary Data 10). Pair-
wise comparison of all gut mOTUs for treatment effect in the
follow-up patients revealed 48 differentially abundant bacterial
species (P < 0.05 and FDR= 0.420, Paired Wilcoxon rank sum
test; Benjamini and Hochberg method, Supplementary Data 11).
However, only 5 of the 48 differentially abundant species were
included in the 26 mOTUs schizophrenia classifiers. This result
suggests that antipsychotic treatment influences the gut micro-
biota, but does not completely restore the altered microbiota
associated with schizophrenia.
S. vestibularis induced schizophrenia-like behaviors in mice. S.
vestibularis contributed to discriminate patients from controls and
was associated with serum GABA, tryptophan, KYNA, and the
Brief Assessment of Cognition in Schizophrenia (BACS) scores in
MATRICS Consensus Cognitive Battery (MCCB) test (Fig. 3 and
Supplementary Fig. 2). Moreover, S. vestibularis, present in the gut
of a number of schizophrenic patients, was predicted to have
GBMs related to glutamate synthesis, GABA degradation, and
isovaleric acid synthesis (Fig. 2). As some pathogenic species
of Streptococcus are known to enter the brain26, and have
been implicated in pediatric acute-onset neuropsychiatric
syndrome27,28, we asked if S. vestibularis might play a role in the
pathophysiology of schizophrenia. Hence, we transplanted S.
vestibularis ATCC 49124, using oral gavage and drinking water,
into C57BL/6 mice after antibiotics-based microbiota depletion
(Supplementary Fig. 4). Another strain of Streptococcus, S. ther-
mophilus ST12, which is widely present in the human gut, was
used as a bacterial control. Behavioral tests were performed to
evaluate the effect of S. vestibularis transplantation (Fig. 4a).
Quantitative polymerase chain reaction (q-PCR) used to quantify
the 16S rRNA gene of S. vestibularis and S. thermophilus, revealed
that their concentration increased by 4,164- and 6,183-fold
immediately after transplantation and remained at a 31.2- and
58.1-fold increase after the behavioral tests as compared to the
control mice (Supplementary Fig. 5). Compared to control mice
gavaged with saline or with S. thermophilus, the S. vestibularis-
treated mice exhibited an increase in the total traveled distance
and times of rearing during a 30-minute open-field test (Fig. 4b,
d). They continued their hyperlocomotion after the 10-minute
habituation period and showed no obvious decline in locomotion
activity after a period of 30-minutes (Fig. 4c). In the three-
chamber social test, the S. vestibularis mice displayed obvious
deficits in sociability and social novelty, as they were much less
sociable and avoided social novelty (Fig. 4e–g). However, in
Barnes maze, elevated plus maze, and tail suspension test, the mice
transplanted with S. vestibularis displayed spatial memory func-
tion, depressive state, and anxiety levels similar to either saline or
S. thermophilus-treated mice (Supplementary Fig. 6). There were
no significant changes in body weight, systemic pro-inflammatory
cytokines, and endotoxin, and HPA axis hormones between S.
vestibularis-treated, S. thermophilus-treated, and control mice
(Supplementary Fig. 7 a–i).
We then compared the transcriptome and neurotransmitter
levels between S. vestibularis-treated and saline-treated mice in
peripheral tissues and brain. S. vestibularis-treated mice had
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Fig. 3 Gut microbiome-based discrimination between schizophrenic patients and healthy controls. a Receiver operating characteristic curve (ROC)
according to 171 samples of the discovery set (green line) and 90 independent validation samples (pink line) calculated by cross-validated random forest
models. Area under ROC (AUC) and the 95% confidence intervals are also shown. b The 26 mOTUs with most weight to discriminate schizophrenic (SCZ)
patients and healthy controls (HC) were selected by the cross-validated random forest models. The length of line indicates the contribution of the mOTU
to the discriminative model. The color of each mOTU indicates its enrichment in schizophrenic patients (blue) or healthy controls (red) or no significant
direction (black), respectively. c Spearman’s correlation of 26 mOTUs classifiers with three types of neurotransmitter in serum (green), seven types of
cognitive function evaluated using the MATRICS Consensus Cognitive Battery (purple), and with the positive score and the negative score of the Positive
and Negative Syndrome Scale (light green). Only significant associations are displayed with correlation coefficient (P-value < 0.05). d The relative
abundance (log10) of 26 mOTUs classifiers in 90 HCs and 38 SCZ patients at baseline and on a follow-up (3 months later). The dot represents one value
from individual participants and boxes represent the median and interquartile ranges (IQRs) between the first and third quartiles; whiskers represent the
lowest or highest values within 1.5 times IQR from the first or third quartiles. Outliers are not shown. GABA: 4-aminobutyric acid; TMT: Trail Making Test;
BACS: Brief Assessment of Cognition in Schizophrenia; Fluency: Category Fluency in Animal Naming; WMS-III: Wechsler Memory Scale-Third Edition for
working memory; HVLT-R: Hopkins Verbal Learning Test-Revised for visual learning; NAB: Neuropsychological Assessment Battery for reasoning and
problem solving; MSCEIT: Mayer-Salovey-Caruso Emotional Intelligence Test for social cognition. See detailed statistical data in supplementary Source
Data file.
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significantly lower levels of dopamine in serum, intestinal
contents, and colonic tissue, as well as decreased GABA levels
in the intestinal contents immediately after the transplantation,
but these effects disappeared 10 days post-transplantation
(Supplementary Fig. 8b, e, h, f). Intestinal contents of S.
vestibularis-treated mice showed increased levels of 5-HT
throughout the behavioral tests (Supplementary Fig. 8d). S.
vestibularis transplantation did not induce obvious inflammatory
cell infiltration (Supplementary Fig. 7j), but induced changes in
the expression of numerous immune/inflammation-related genes
in the intestine when compared with mice receiving saline gavage
(Supplementary Data 12a, b). By gene enrichment analysis, we
found that these genes were enriched in cytokine-cytokine
receptor interaction, chemokine signaling pathways, leukocyte
trans-endothelial migration, complement and coagulation cas-
cades, antigen processing and presentation, intestinal immune
network for IgA production, and inflammatory bowel disease
(Supplementary Fig. 9a, b). These results suggested that S.
vestibularis may influence gut immune homeostasis. In the brain,
the levels of neurotransmitters were not affected by
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Kruskal-Wallis test followed by Dunn’s multiple comparisons test (d), or two-way (ANOVA) followed by Sidak’s multiple comparisons test (e–g). See
detailed statistical data in supplementary Source Data file.
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transplantation with S. vestibularis and only tryptophan
decreased in the prefrontal cortex of S. vestibularis-treated mice
(Supplementary Data 13). However, we observed 354, 540, and
470 significantly differentially expressed gene in the PFC,
striatum, and hippocampus, respectively, between S. vestibu-
laris-treated and saline-treated mice (Supplementary Data 12c–e).
The pathways influenced by these differentially expressed genes
include defense responses and immune-regulating pathways,
similar to the observed differentially expressed genes in the
intestine, as well as peroxisome proliferator-activated receptor
signaling pathway, steroid biosynthesis, tyrosine, and tryptophan
metabolism (Supplementary Fig. 9c–e).
Discussion
We here used MWAS to systematically screen for schizophrenia-
associated gut microbes and identified a number of
schizophrenia-associated GBMs, expanding our insight into
functional changes characterizing the gut microbiota of schizo-
phrenic patients. Consistent with the MWAS results and the
inferred microbial functions, the schizophrenia-associated bac-
terium Streptococcus vestibularis was shown in mice to have a
functional neuroactive potential20 associated with changes in
animal behaviors.
MWAS for the gut microbiome has been controversial due to
population differences, diet and medication, and technical dif-
ferences29. With more data from different cohorts, gut micro-
biome characteristics associated with colorectal cancer have
already converged29,30. In the present study, a diagnostic model
of 26 mOTUs obtained by using a discovery cohort, which
included medication-free patients, was well validated in a testing
cohort, which included patients taking antipsychotics. We chose
to investigate medication-free patients in the discovery cohort in
order to eliminate the possible effects of antipsychotics on the gut
microbiota to identify gut bacteria possibly involved in the
development of schizophrenia. The validation of the initial
findings in patients taking antipsychotics demonstrated that
abundances of these microbial species are, to a certain extent,
independent of antipsychotics. Follow-up analysis also revealed
that 22 of the 26 identified mOTUs in the diagnostic model
remained the same over a treatment duration of three months.
Therefore, most microbial species associated with schizophrenia
seem stable and are not sensitive to current antipsychotics.
Analysis of the bacterial V3-V4 region of the 16S rRNA gene
regions has a limited resolution in terms of identification of bac-
terial species17,22,31. Current 16S rRNA gene amplicon sequencing
generally capture reliable taxonomic classification at the genus
level31. However, several recent analyses indicate that many
taxonomic associations might be presented only at the species
level17,32,33. Accordingly, most of the schizophrenia-associated
microbial species revealed by the MWAS results were not iden-
tified in previous studies by using 16S rRNA gene
sequencing14,34,35. There are more overlaps of findings at the
genus level between our findings and the previous studies (Sup-
plementary Data 5b), including six genera in the study of Zheng
et al. (Acidaminococcus, Akkermansia, Alistipes, Citrobacter,
Dialister, Veillonella)14, one in the study of Schwarz et al. (Lac-
tobacillus)35, one in the study of Shen et al. (Methanobrevibacter)
34.
Surprisingly, gut microbiota diversities based on genus level
taxonomy and annotated genes were higher in schizophrenic
patients than in controls. In accordance with our data, both α
diversity and β diversity exhbited an increase in the blood
microbiota of schizophrenic patients36. The microbes in blood are
thought to originate from the gut as well as from the oral
cavities37,38. Moreover, the increased diversity of the blood
microbiota may be due to the nonspecific overall increased
microbial burden in schizophrenia36, which is supported by our
observed increased microbial gene number in the gut of schizo-
phrenic patients. The considerable heterogeneity in the etiology
and clinical manifestation of schizophrenia39,40 may be impli-
cated in such an increase in the microbiota diversity. Another
notable feature of the gut microbiota in schizophrenia is the
significant enrichment of oral cavity resident bacteria. Increased
bacterial translocation due to a leaky gut and innate immune
imbalance are both presented in patients with schizophrenia41,42.
Furthermore, gastrointestinal inflammation due to a dysfunc-
tional immune response to pathogen infections and food antigens
is also prevalent in schizophrenia43,44. These intestinal patholo-
gical conditions may disrupt the mucosal barrier and decrease
immune surveillance towards foreign microbes7, increasing the
possibility of observing oral bacteria in the gut.
The composition of human gut microbiota has recently been
linked to schizophrenia14,34,35, but knowledge of individual
microbial species is needed to decipher their biological role45. We
still do not completely understand the functions of most of the
schizophrenia-associated microbes identified in the present study
or their biological roles in schizophrenia. Intriguingly, some
schizophrenia-enriched bacterial species identified in the present
study are also over-represented in subjects with metabolic dis-
orders and atherosclerotic cardiovascular diseases46–49. Schizo-
phrenic patients are more likely to develop obesity,
hyperglycemia/diabetes, hypertension, and cardiovascular disease.
Additionally, some of these risks are independent of the effects of
antipsychotic administration and healthy lifestyle choices50–53.
Several prenatal and early-life risk factors are shared by schizo-
phrenia, metabolic disorders, and cardiovascular diseases such as
prenatal famine, postnatal growth restriction, the quality of fetal
growth, and low birth weight54–60. Gut microbes enriched in both
schizophrenia and metabolic disorders/cardiovascular disease
may account for the increased risk of these comorbidities in
schizophrenia. Moreover, new evidence also indicates that
metabolic disorders in schizophrenia are not only comorbidities,
but also affect pathogenesis, such as the manifestation of negative
symptoms61, cognitive function62, and brain white matter dis-
ruption63. Treating metabolic disorders via physical activity and
psychosocial and dietary interventions, is also an effective
approach to improve the symptoms of schizophrenia62. There-
fore, manipulation of gut microbes may have double therapeutic
potential for both metabolic disorders and schizophrenia.
Using GBMs which were manually curated according to
existing knowledge, we identified 27 schizophrenia-associated
GBMs, which provides clues as to how the gut microbiota might
modulate the pathophysiology of schizophrenia. Among these
GBMs, a few well-known molecular entities associated with
schizophrenia were covered, such as several types of neuro-
transmitters2–4 and tryptophan metabolites64,65. Furthermore,
some microbes harboring these GBMs were significantly asso-
ciated with the serum levels of several neurotransmitters and
tryptophan metabolites. Parallel to the present study, our pre-
vious animal study demonstrated that transplantation of fecal
microbiota from medication-free patients with schizophrenia into
specific pathogen-free mice could cause schizophrenia-like
behavioral abnormalities and dysregulated kynurenine metabo-
lism66. The consistent findings of altered tryptophan-kynurenine
metabolism revealed by human serum metabolite analysis,
microbiota-based GBM prediction, and mouse studies suggest
that this pathway is an important link between schizophrenia and
gut microbiota dysbiosis. Of note, transplantation of one bacteria,
S. vestibularis ATCC 49124, possessing 11 GBMs involved in
synthesis and degradation of several types of neurotransmitter
induced abnormal behaviors in the recipient mice. The
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schizophrenia-enriched S. vestibularis contributed to the expres-
sion of two types of schizophrenia-relevant behaviors (hyper-
activity and impaired social behaviors) in mice, suggesting that
GBM prediction is an effective way to screen out potentially
functional gut microbes. To the best of our knowledge, this is the
first study which aims to determine the functional roles of a single
bacterium associated with schizophrenia in disease pathogenesis.
Although the biological mechanisms underlying the effects of S.
vestibularis are still unclear, our data indicate profound influences
of this microbe on brain neurotransmitters, and underscore the
value of combining MWAS from human cohorts with studies in
animals66. In conclusion, our study identified a number of
schizophrenia-associated bacterial species representing potential
microbial targets for future treatment and emphasizes the likely
importance of microbial metabolites affecting the development of
schizophrenia.
Methods
Subject recruitment and clinical assessment. The present study followed the
Declaration of Helsinki and was approved by the Medical Ethics Committee of The
First Affiliated Hospital of Xi’an Jiaotong University (TFAHXJTU). It is a publicly
registered clinical trial (Identifier: NCT02708316; https://clinicaltrials.gov). Written
informed consent was obtained from all participants. Only acutely relapsed schi-
zophrenic (ARSCZ) and first-episode schizophrenic (FESCZ) patients were recrui-
ted in this study. Diagnoses were established on the Diagnostic and Statistical
Manual of Mental Disorders, fourth Edition (DSM-IV). Healthy controls did not
have any mental disorders and were well-matched to the patients on demographic
features (Supplementary Data 1 and 9). We interviewed 38 of the schizophrenic
patients three months after they joined the project. The antipsychotics dosage,
therapeutic response, and side effects were recorded via interview or questionnaire.
All assessments were conducted independently by two psychiatrists on the day when
the blood samples were collected. Clinical psychopathological symptoms were
evaluated by the Positive and Negative Syndrome Scale (PANSS) (Supplementary
Data 2)67. Cognitive functioning was assessed via the MATRICS Consensus Cog-
nitive Battery (MCCB; the data are showed in Supplementary Data 3)68,69. Detailed
information on subjects recruitment is presented in the Online methods.
Shotgun metagenomic sequencing. Metagenomic shotgun sequencing was per-
formed on Illumina platform for human fecal samples of the discovery cohort
(paired end library of 350-bp and 150-bp read length). Adaptor and low- quality
reads were discarded from the raw reads, and the remaining reads were filtered in
order to eliminate host DNA based on the human reference genome as described
previously70. Shotgun metagenomic sequencing was performed on the BGISEQ-
500 platform for the validation cohort with single-end library and read length of
100 bp. Low-quality reads and host reads were removed71. On average, 11.46 Gb
and 13.13 Gb of high-quality non-host sequences were obtained per sample in the
discovery cohort and the validation cohort, respectively (Supplementary Data 4 and
Table 9).
Taxonomic and functional profiling. High-quality reads in each sample were
aligned to the sequences of a mOTU reference with default parameters72 and 545
species-level mOTUs were identified. The gene profile was constructed by aligning
high-quality reads to the 11.4 M gene catalog21 by SOAP v2.22 (-m 100 -x 600 -v 8
-p 4 -l 32 -r 1 -M 4 -c 0.95)73. The gene abundance was used to calculate alpha
diversity, beta diversity. KO assignment was performed using the same procedure
as described previously21. Putative amino acid sequences were translated from the
gene catalog and aligned against the proteins/domains in the KEGG databases
(release 79.0, with animal and plant genes removed) using BLASTP (v2.2.24,
default parameter except that -e1e -5a6 -b50 -FFm8). Each protein was assigned to
a KO by the highest scoring annotated hit(s) containing at least one high-scoring
segment pair (HSP) scoring over 60 bits.
Rarefaction curve analysis. The rarefaction curve was generated to assess the
gene richness in the schizophrenic patients and healthy controls74. We performed
random subsampling 100 times in the cohort with replacement and estimated the
total number of genes that could be identified from a given number of samples.
α-diversity and β-diversity. α-diversity (within-sample diversity) was calculated
using the Shannon index depending on the gene and mOTU profile46. β-diversity
(between-sample diversity) was estimated by Bray-Curtis dissimilarity.
MWAS. Of the 545 identified mOTUs, we removed mOTUs present in less than
5% of the samples and focus on the remaining 360 mOTUs. The relative abundance
of each mOTU was compared between the patients and controls via Wilcoxon rank
sum test followed by a Storey’s FDR correction. Moreover, mOTUs were correlated
with diagnosis via Semi-partial Spearman correlation tests (R package ppcor)
adjusting for diet, BMI, age, and gender. The co-occurrence network was visualized
using Cytoscape 3.4.0. Pair-wise comparison of all gut mOTUs before and after
treatment in the patients with follow-up was conducted via paired Wilcoxon rank
sum test with a mutilple testing correction of Benjamini and Hochberg.
Five-fold cross-validation was performed ten times on a random forest model
using the mOTUs abundance profiles of the schizophrenic patients and HCs. The
test error curves from ten trials of five-fold cross-validation were averaged. We
chose the model which minimized the sum of the test error and its standard
deviation in the averaged curve75. The probability of schizophrenia was calculated
using this set of mOTUs and a receiver operating characteristic (ROC) was drawn
(R 3.3.2, pROC package). The correlation between gut bacteria abundance and host
phenotypes (MCCB, PANSS, neurotransmitter) was calculated by Spearman’s
correlation. The relationship between “overall diet” and microbial classifier was
analyzed by mantel test (ade4 package 1.7–13) revealing that no significant
correlation existed between them (P= 0.78). Finally, we assessed the possible
confounding effects of age, BMI, sex and diet on our random forest model
following the procedures of Zeller, et al.75 (chi-square test, Supplementary Data 8).
Functional modules predicted from metagenomics. Bacterial functions were
analyzed using two methods, (1) the reporter score and (2) gut–brain modules
(GBMs)20. The first method depended on the reporter score. Differentially enri-
ched KEGG modules were identified according to their reporter score from the Z-
scores of individual KOs. An absolute value of reporter score= 1.96 or higher (95%
confidence according to a normal distribution) was used as a detection threshold
for modules that differed significantly in abundance74,76. The second method
involved the use of the 56 GBMs20 and PanPhlAn23. Firstly, we built species
profiles and species-specific gene families in our 171 samples, using PanPhlAn
(–min_coverage 1 –left_max 1.7 –right_min 0.3). Then, GBM profiles present in
the samples were derived by mapping species-specific gene families to the GBM
database (blastx, identity 35, score 60, top 1), for each species, and profiling by
using the Omixer-RPM version 1.0 (https://github.com/raeslab/omixer-rpm).
Finally, species exhibiting significant differences in abundance were identified (chi-
square test, p < 0.05, FDR= 0.16, Benjamini and Hochberg method, Supplemen-
tary Data 7).
Animals experiment. Male C57BL/6 J mice were obtained from the Experimental
Animal Center of Xi’an Jiaotong University Medical College (five weeks of age; 4–5
per cage). The mice were maintained in a temperature-controlled (21–23 °C)
specific pathogen-free level environment with a relative humidity 55 ± 10% and 12/
12-h light–dark cycle. Mice were given water and commercial standard feed
(produced according to national standard of China for laboratory mouse feed, GB
14924.3) ad libitum. All animal procedures were approved by the Animal Care and
Use Committee of Xi’an Jiaotong University. The animal experimental procedure is
schematically shown in Supplementary Fig. 4. The body weight was measured, and
feces were collected during the single bacterium transplantation experiments and
during behavioral tests. The mice were subjected to a series of behavioral task to
evaluate the effects of S. vestibularis transplantation on locomotor, learning and
memory, social behavior, and anxiety and depression level (see Online methods).
Mice were killed 24 h after the last behavioral test and peripheral tisses and brain
were collected and stored at −80 °C.
Dopamine, gamma-aminobutyric acid, serotonin, kynurenine, kynurenic acid in
human serum and mouse serum, as well as the cytokines (IL-1 beta, IFN-γ, and TNF-
α) and neurotransmitters (dopamine, 4-aminobutyric acid, 5-hydroxytryptamine) in
mouse gut were quantified by Enzyme Linked Immunosorbent Assay (ELISA)
according to the manufacturer’s instructions (R&D). The detection range, sensitivity,
and assay precision are described in Supplementary Data 14. Readings from colonic
tissue samples were normalized to total protein content as detected by BCA assay
(Sigma-Aldrich, Shanghai, China). Readings from intestinal contents were normalized
to total mass of sample. Tryptophan in serum of humans and mice were quantified by
liquid chromatography-mass spectrometer. Moreover, tissue concentrations of
dopamine (DA), serotonin (5-HT), 4-aminobutyric acid (GABA), and tryptophan in
the prefrontal cortex (PFC), the striatum, and the hippocampus of mouse brain were
quantified via ultra-high-performance liquid chromatography-tandem mass-
spectrometry assay (see Online methods and Supplementary Data 13). Transcriptomes
in mice gut and brain were analysis via RNA-seqencing on an Illumina HiSeq 2500
(Illumina, Santiago, CA, USA), at Shanghai Genergy Co., Ltd. (Shanghai, China). Gene
expression levels were presented as FPKM- Fragments Per Kilobase of transcript per
Million fragments mapped. The enriched biological functions and pathways associated
with significantly differentially expressed genes were annotated using gene ontology
enrichment analysis and Kyoto Encyclopedia of Genes and Genomes terms.
Culture and transplantation of S. vestibularis. S. vestibularis (ATCC 49124) was
bought from ATCC (https://www.atcc.org). The strain of S. thermophilus ST12 was
bought from the Baiobowei company (Beijing, China). The bacteria were cultured
according to the provider’s instructions, and after washing twice with sterile PBS,
they were resuspended in sterile saline at a concentration of 108 and 109 per mL, to
be used for oral gavage and drinking water, respectively. Twenty-four hours after
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the last gavage of antibiotics, mice were randomly divided into three groups
receiving S. vestibularis, S. thermophilus or saline, respectively. S. vestibularis or S.
thermophilus was provided to the mice via oral gavage (once per day on Day 1–4, 6,
8) and in drinking water for 11 days (drinking water was changed every day). To
maintain a high level of the two Streptococcus species in the gut of the mice, the
mice were offered drinking water with bacteria or saline again for 24 h in the
middle of the session of behavioral tests. The schematic of bacterial transplantation
and behavioral test is shown in Supplementary Fig. 4. The bacterial abundance in
mice gut was measured by real-time quantitative PCR targeting specific DNA
sequence in the 16S rRNA gene of the corresponding bacterial genome (Supple-
mentary Data 15).
Statistical analyses. Behavioral data are shown as mean ± standard error of the
mean (SEM). The comparisons between the three groups (saline, S. vestibularis or
S. thermophilus-treated mice) were carried out using one-way variance analysis
(ANOVA) followed by Tukey’s multiple comparisons tests or Kruskal-Wallis test
and Dunn’s multiple comparisons tests. Comparisons regarding repeated weight
and the latency to locate escape hole in Barnes maze test were conducted via two-
way ANOVA, in accordance with Sidak’s multiple comparisons test. Generally,
statistical significance is set to 0.05, and Bonferroni correction was applied to the
level of significance for multiple testing. All behavioral-related graphs and statis-
tical analyses were generated using GraphPad Prism software, unless otherwise
stated. P-values, n values, definition of center, and dispersion measurements are
indicated in the associated figure legends for each figure.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Metagenomic sequencing data for donors and mice samples have been deposited in the
CNGB Nucleotide Sequence Archive (CNSA) database under accession identification
CNP0000119 and in the European Nucleotide Archive(ENA) database under accession
identification code ERP111403. The source data underlying all figures except for those
not including statistics are provided as a Source Data file.
Code availability
The following softwares were used: SOAP v2.22, BLASTP v2.2.24, mOTUs v1, Cytoscape
v3.4.0, PanPhlAn v1.2.2.3, Omixer-RPM v1.0, GraphPad Prism v7.0, STAR v2.5.3.a,
DESeq2 v1.16.1. The following R packages were used: ppcor 1.0, pROC 1.12.1,
randomForest 4.6–14, ade4 1.7–13.
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